No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VNDA240517P6000
- 0.75
- -0.05-6.25%
15min DelayClose May 8 16:00 ET
0.75High0.75Low
0.75Open0.80Pre Close2 Volume209 Open Interest6.00Strike Price150.00Turnover275.92%IV-12.78%PremiumMay 17, 2024Expiry Date0.64Intrinsic Value100Multiplier9DDays to Expiry0.11Time Value100Contract SizeAmericanOptions Type-0.5157Delta0.1711Gamma4.05Leverage Ratio-0.0522Theta-0.0009Rho-2.09Eff Leverage0.0034Vega
Intraday
- 5D
- 1D
News
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
Vanda Pharma Q1 2024 GAAP EPS $(0.07) Misses $0.05 Estimate, Sales $47.462M Miss $48.500M Estimate
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.05 by 240 percent. The company reported quarterly sales of $47.462 million
Express News | Vanda Pharmaceuticals Inc: Revenues for Q1 2024 Were $47.5 Mln
Express News | Vanda Pharmaceuticals Inc - Unable to Provide 2024 Financial Guidance at This Time
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M
04:01 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M
Express News | Vanda Pharmaceuticals Q1 EPS USD -0.07
Comments
Future Pak's Strategic Move to Acquire Vanda Pharmaceuticals: A Comprehensive Analysis.
We found a bold and calculated maneuver, Future Pak LLC ("Future Pak") has stepped up its acquisition game by enhancing its offer for Vanda Pharmaceuticals Inc. ("Vanda" or "the Company"), signaling a pivotal moment in the pharmaceutical industry's mergers and acquisitions landscape. This revised proposal not only raises the cash consideration but notably...
We found a bold and calculated maneuver, Future Pak LLC ("Future Pak") has stepped up its acquisition game by enhancing its offer for Vanda Pharmaceuticals Inc. ("Vanda" or "the Company"), signaling a pivotal moment in the pharmaceutical industry's mergers and acquisitions landscape. This revised proposal not only raises the cash consideration but notably...
$Vanda Pharmaceuticals(VNDA.US$ Are you gonna go up for a bit more? Or will you fall like most of the market right now? Hehehe
$Vanda Pharmaceuticals(VNDA.US$ Benzinga· 7 mins ago
Future Pak Increases Bid For Vanda Pharmaceuticals To Include CVRs In Addition To $7.25-$7.75 Per Share In Cash; Offer Represents $11.62-$12.12 Per Share
Future Pak Increases Bid For Vanda Pharmaceuticals To Include CVRs In Addition To $7.25-$7.75 Per Share In Cash; Offer Represents $11.62-$12.12 Per Share
4
Read more